EA199800434A1 - Treatment of traumatic brain injury - Google Patents

Treatment of traumatic brain injury

Info

Publication number
EA199800434A1
EA199800434A1 EA199800434A EA199800434A EA199800434A1 EA 199800434 A1 EA199800434 A1 EA 199800434A1 EA 199800434 A EA199800434 A EA 199800434A EA 199800434 A EA199800434 A EA 199800434A EA 199800434 A1 EA199800434 A1 EA 199800434A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
traumatic brain
brain injury
traumatic
methylpyridine
Prior art date
Application number
EA199800434A
Other languages
Russian (ru)
Other versions
EA000531B1 (en
Inventor
Брайан Р. Пайк
Original Assignee
Х.Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х.Лундбекк А/С filed Critical Х.Лундбекк А/С
Publication of EA199800434A1 publication Critical patent/EA199800434A1/en
Publication of EA000531B1 publication Critical patent/EA000531B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Соединение 5-(2-этил-2Н-тетразол-5-ил)-1,2,3,6-тетрагидро-1-метилпиридин формулы (I) улучшает познавательную функцию, и ослабляет вызванное травмой уменьшение холинергических нейронов в моделях травматического повреждения головного мозга, и является полезным для производства фармацевтических препаратов для лечения травматического повреждения головного мозга.Международная заявка была опубликована вместе с отчетом о международном поиске.The compound 5- (2-ethyl-2H-tetrazol-5-yl) -1,2,3,6-tetrahydro-1-methylpyridine of formula (I) improves cognitive function and weakens trauma-induced reduction in cholinergic neurons in models of traumatic head injury brain, and is useful for the manufacture of pharmaceuticals for the treatment of traumatic brain damage. An international application was published along with an international search report.

EA199800434A 1995-11-06 1996-11-05 Active substance for production of pharmaceutical preparation for treatment of traumatic brain injury EA000531B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK123295 1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Publications (2)

Publication Number Publication Date
EA199800434A1 true EA199800434A1 (en) 1998-10-29
EA000531B1 EA000531B1 (en) 1999-10-28

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800434A EA000531B1 (en) 1995-11-06 1996-11-05 Active substance for production of pharmaceutical preparation for treatment of traumatic brain injury

Country Status (18)

Country Link
EP (1) EP0866706A1 (en)
JP (1) JPH11514654A (en)
KR (1) KR19990067353A (en)
AU (1) AU706594B2 (en)
BG (1) BG63150B1 (en)
BR (1) BR9611396A (en)
CA (1) CA2234824A1 (en)
CZ (1) CZ287441B6 (en)
EA (1) EA000531B1 (en)
HU (1) HUP9901051A2 (en)
IS (1) IS4726A (en)
NO (1) NO982036L (en)
NZ (1) NZ321546A (en)
PL (1) PL326490A1 (en)
SK (1) SK58198A3 (en)
TR (1) TR199800801T2 (en)
WO (1) WO1997017074A1 (en)
ZA (1) ZA969320B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (en) * 1997-07-01 2000-12-13 Lundbeck & Co As H SALE OF ADDITION OF MALEIC ACID OF 5- (2-ETIL-2-H-TETRAZOL-5-IL) -1-METHYL-1,2,3,6-TETRAHIDROPIRIDINA, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT, ITS USE IN THERAPY AND METHOD OF PREPARATION OF THE SAME.
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Also Published As

Publication number Publication date
IS4726A (en) 1998-04-27
BG102480A (en) 1999-01-29
CA2234824A1 (en) 1997-05-15
CZ287441B6 (en) 2000-11-15
WO1997017074A1 (en) 1997-05-15
BR9611396A (en) 1999-07-13
NZ321546A (en) 2000-12-22
EA000531B1 (en) 1999-10-28
SK58198A3 (en) 1998-10-07
NO982036L (en) 1998-06-25
MX9803432A (en) 1998-09-30
BG63150B1 (en) 2001-05-31
TR199800801T2 (en) 1998-08-21
AU706594B2 (en) 1999-06-17
KR19990067353A (en) 1999-08-16
JPH11514654A (en) 1999-12-14
HUP9901051A2 (en) 2000-03-28
AU7490096A (en) 1997-05-29
CZ138998A3 (en) 1998-10-14
ZA969320B (en) 1997-05-30
NO982036D0 (en) 1998-05-05
PL326490A1 (en) 1998-09-28
EP0866706A1 (en) 1998-09-30

Similar Documents

Publication Publication Date Title
DE69523350T2 (en) Treatment of hyperproliferative vascular diseases
EA199900620A1 (en) Phthalasins
DE19680619D2 (en) Use of adamantane derivatives for the treatment of diseases of the inner ear
DE69429717D1 (en) HETEROCYCLIC COMPOUNDS AND THEIR PRODUCTION AND USE
ATE168007T1 (en) BENZIMIDAZOLES USED IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES
ATE194617T1 (en) HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE
ATE102196T1 (en) GLYCOSIDASE INHIBITOR SALBOSTATIN, PROCESS FOR ITS PRODUCTION AND ITS USE.
EA199800434A1 (en) Treatment of traumatic brain injury
ATE150307T1 (en) INHIBITING SEBORRHEA AND ACNE
FI932105A0 (en) Sulfonylbenzyl substituents benzo and pyridopyridoner
DE69331171T2 (en) Quinoline and quinazoline derivatives for the treatment of arthritis
NO943874L (en) Treatment of resistant neoplasm
ATE131154T1 (en) PHENYLALKANEOUS ACIDS.
DE69110507T2 (en) Ester derivatives of siloxanes and cosmetic compositions containing these derivatives.
ITMI931164A0 (en) NEW PIPERIDIN-TRIAZINE COMPOUNDS SUITABLE FOR USE AS LIGHT, HEAT AND OXIDATION STABILIZERS FOR ORGANIC MATERIALS
DE69000884D1 (en) COSMETIC USE OF DIORGANOPOLYSILOXANS WITH 2-HYDROXYBENZOPHENONE SUBSTITUTES, COSMETIC AGENTS THAT CONTAIN THESE COMPOUNDS TO PROTECT THE SKIN AND HAIR.
FI935092A0 (en) D3 vitaminanaloger
DE69419954D1 (en) Medicines for the treatment of skin diseases
DE69825981D1 (en) 4,5-dihydroxy-2-cyclopenten-1-one for the treatment of diabetes mellitus
DE69825980D1 (en) 4,5-DIHYDROXY-2-CYCLOPENTENE-1-ON FOR THE TREATMENT OF RHEUMATISM, INFLAMMATION AND AUTOIMMUNE DISEASES
ES2123728T3 (en) DERIVATIVES OF PYRROLLO-PYRAZINE ACTIVITY 5-HT3.
DE3778642D1 (en) THERAPEUTIC FOR TREATMENT OF STOMACH.
NO942668L (en) Alkyl derivatives of trazodone with CNS activity
EA199900539A1 (en) APPLICATION OF AMINOISOTHIAZOLES AS MICROBICIDES
BR8906421A (en) PROCESS FOR THE PREPARATION OF PYRIDINE-3-PEROXICARBOXYLIC ACID MONOPERSULPHATE

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU